$395.1 M

INSY Mkt cap, 04-Dec-2018

$18.3 M

Insys Therapeutics Revenue Q3, 2018
Insys Therapeutics Gross profit (Q3, 2018)16 M
Insys Therapeutics Gross profit margin (Q3, 2018), %87%
Insys Therapeutics Net income (Q3, 2018)-30.5 M
Insys Therapeutics EBIT (Q3, 2018)-30.8 M
Insys Therapeutics Cash, 30-Sep-201820.8 M

Insys Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

99.3m222.1m330.8m242.3m140.7m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7m28.9m25.4m20.6m

Gross profit

86.6m301.9m216.9m120.1m

Gross profit Margin, %

87%91%90%85%

Sales and marketing expense

29.2m80.7m69.7m48.9m

R&D expense

8.5m55.3m73.9m63.0m

General and administrative expense

16.4m64.0m62.1m67.6m

Operating expense total

54.1m209.5m209.6m339.1m

EBIT

32.6m64.0m92.4m7.3m(219.0m)

EBIT margin, %

33%29%28%3%(156%)

Interest expense

928.0k

Interest income

502.0k1.0m1.9m

Pre tax profit

31.6m93.0m8.4m(217.2m)

Income tax expense

8.8m10.8m

Net Income

40.4m38.0m58.5m7.6m(228.0m)

Quarterly

Insys Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.4m58.1m79.5m104.6m32.0m

Accounts Receivable

Inventories

14.5m34.8m41.7m21.7m17.4m

Current Assets

82.2m151.0m253.2m231.0m175.9m

PP&E

10.1m38.4m43.2m55.2m

Total Assets

100.6m215.1m351.2m356.1m279.1m

Accounts Payable

16.6m27.5m36.4m27.4m30.4m

Short-term debt

Current Liabilities

21.1m45.7m88.9m78.6m207.2m

Long-term debt

Total Debt

Total Liabilities

21.1m97.5m86.5m215.8m

Common Stock

354.0k719.0k719.0k736.0k

Preferred Stock

Additional Paid-in Capital

168.5m216.4m245.7m256.5m278.4m

Retained Earnings

(89.0m)(51.1m)7.4m12.7m(215.4m)

Total Equity

79.5m165.7m253.7m269.6m63.3m

Financial Leverage

1.3 x1.3 x1.4 x1.3 x4.4 x

Insys Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

40.4m58.5m7.6m(228.0m)

Depreciation and Amortization

1.8m2.5m5.3m6.2m7.3m

Accounts Receivable

(13.2m)(10.0m)(21.9m)26.6m(859.0k)

Inventories

(7.4m)(20.0m)(6.9m)15.0m2.3m

Accounts Payable

Cash From Operating Activities

24.2m49.7m100.9m58.9m(60.7m)

Purchases of PP&E

(5.1m)(22.2m)(13.8m)(10.6m)(16.7m)

Cash From Investing Activities

(5.5m)(69.9m)(88.7m)(22.0m)(17.8m)

Cash From Financing Activities

26.3m32.9m9.3m(11.7m)5.8m

Income Taxes Paid

991.0k3.0m15.4m10.7m2.1m

Insys Therapeutics Ratios

USDY, 2018

Financial Leverage

1.6 k x
Report incorrect company information

Insys Therapeutics Employee Rating

2.259 votes
Culture & Values
1.6
Work/Life Balance
2.2
Senior Management
1.7
Salary & Benefits
2.2
Career Opportunities
1.9
Source